Report Detail
Global Chemotherapy-induced Nausea and Vomiting Drugs Market Insights, Forecast to 2025
- RnM3447726 |
- 22 May, 2019 |
- Global |
- 119 Pages |
- QYResearch |
- Pharma & Healthcare
Chemotherapy induced nausea and vomiting (CINV) drugs refer to medication or treatment that is offered to cancer patients who experience nausea and vomiting due to chemotherapy.
The classification of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs includes 5-HT3 Inhibitors, NK1 Inhibitors and others. The proportion of 5-HT3 Inhibitors in 2017 is about 62%, and the proportion of NK1 Inhibitors in 2017 is about 33%.
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs are application for Highly Emetogenic Chemotherapy, Moderately Emetogenic Chemotherapy, Low Emetogenic Chemotherapy and others. The most of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs is used for Moderately Emetogenic Chemotherapy, and the market share of that is about 52 % in 2017.
North America is the largest consumption place, with a consumption market share nearly 51% in 2017; Europe is the second largest consumption place with the consumption market share of 21% in 2017.
Market competition is not intense. Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis etc. are the leaders of the industry with the market share are about 66% in 2017.
The global Chemotherapy-induced Nausea and Vomiting Drugs market is valued at 1740 million US$ in 2018 and will reach 2460 million US$ by the end of 2025, growing at a CAGR of 4.4% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Chemotherapy-induced Nausea and Vomiting Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Chemotherapy-induced Nausea and Vomiting Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Chemotherapy-induced Nausea and Vomiting Drugs in these regions.
This research report categorizes the global Chemotherapy-induced Nausea and Vomiting Drugs market by top players/brands, region, type and end user. This report also studies the global Chemotherapy-induced Nausea and Vomiting Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro
Market size by Product
5-HT3 Inhibitors
NK1 Inhibitors
Other
Market size by End User
Highly Emetogenic Chemotherapy
Moderately Emetogenic Chemotherapy
Low Emetogenic Chemotherapy
Other
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Chemotherapy-induced Nausea and Vomiting Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Chemotherapy-induced Nausea and Vomiting Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Chemotherapy-induced Nausea and Vomiting Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Chemotherapy-induced Nausea and Vomiting Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Chemotherapy-induced Nausea and Vomiting Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Chemotherapy-induced Nausea and Vomiting Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Chemotherapy-induced Nausea and Vomiting Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size Growth Rate by Product
- 1.4.2 5-HT3 Inhibitors
- 1.4.3 NK1 Inhibitors
- 1.4.4 Other
- 1.5 Market by End User
- 1.5.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size Growth Rate by End User
- 1.5.2 Highly Emetogenic Chemotherapy
- 1.5.3 Moderately Emetogenic Chemotherapy
- 1.5.4 Low Emetogenic Chemotherapy
- 1.5.5 Other
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Size
- 2.1.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue 2014-2025
- 2.1.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales 2014-2025
- 2.2 Chemotherapy-induced Nausea and Vomiting Drugs Growth Rate by Regions
- 2.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Regions
- 2.2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Chemotherapy-induced Nausea and Vomiting Drugs Sales by Manufacturers
- 3.1.1 Chemotherapy-induced Nausea and Vomiting Drugs Sales by Manufacturers
- 3.1.2 Chemotherapy-induced Nausea and Vomiting Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Chemotherapy-induced Nausea and Vomiting Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Manufacturers
- 3.2.1 Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Chemotherapy-induced Nausea and Vomiting Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Chemotherapy-induced Nausea and Vomiting Drugs Price by Manufacturers
- 3.4 Chemotherapy-induced Nausea and Vomiting Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Chemotherapy-induced Nausea and Vomiting Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Chemotherapy-induced Nausea and Vomiting Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Chemotherapy-induced Nausea and Vomiting Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales by Product
- 4.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Product
- 4.3 Chemotherapy-induced Nausea and Vomiting Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Breakdown Data by End User
6 North America
- 6.1 North America Chemotherapy-induced Nausea and Vomiting Drugs by Countries
- 6.1.1 North America Chemotherapy-induced Nausea and Vomiting Drugs Sales by Countries
- 6.1.2 North America Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Chemotherapy-induced Nausea and Vomiting Drugs by Product
- 6.3 North America Chemotherapy-induced Nausea and Vomiting Drugs by End User
7 Europe
- 7.1 Europe Chemotherapy-induced Nausea and Vomiting Drugs by Countries
- 7.1.1 Europe Chemotherapy-induced Nausea and Vomiting Drugs Sales by Countries
- 7.1.2 Europe Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Chemotherapy-induced Nausea and Vomiting Drugs by Product
- 7.3 Europe Chemotherapy-induced Nausea and Vomiting Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs by Countries
- 8.1.1 Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Sales by Countries
- 8.1.2 Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs by Product
- 8.3 Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs by End User
9 Central & South America
- 9.1 Central & South America Chemotherapy-induced Nausea and Vomiting Drugs by Countries
- 9.1.1 Central & South America Chemotherapy-induced Nausea and Vomiting Drugs Sales by Countries
- 9.1.2 Central & South America Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Chemotherapy-induced Nausea and Vomiting Drugs by Product
- 9.3 Central & South America Chemotherapy-induced Nausea and Vomiting Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs by Countries
- 10.1.1 Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Sales by Countries
- 10.1.2 Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs by Product
- 10.3 Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs by End User
11 Company Profiles
- 11.1 Merck
- 11.1.1 Merck Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Merck Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Merck Chemotherapy-induced Nausea and Vomiting Drugs Products Offered
- 11.1.5 Merck Recent Development
- 11.2 Eisai
- 11.2.1 Eisai Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Eisai Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Eisai Chemotherapy-induced Nausea and Vomiting Drugs Products Offered
- 11.2.5 Eisai Recent Development
- 11.3 Mundipharma
- 11.3.1 Mundipharma Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Mundipharma Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Mundipharma Chemotherapy-induced Nausea and Vomiting Drugs Products Offered
- 11.3.5 Mundipharma Recent Development
- 11.4 Qilu Pharma
- 11.4.1 Qilu Pharma Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Qilu Pharma Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Qilu Pharma Chemotherapy-induced Nausea and Vomiting Drugs Products Offered
- 11.4.5 Qilu Pharma Recent Development
- 11.5 Teva
- 11.5.1 Teva Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Teva Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Teva Chemotherapy-induced Nausea and Vomiting Drugs Products Offered
- 11.5.5 Teva Recent Development
- 11.6 Novartis
- 11.6.1 Novartis Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Novartis Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Novartis Chemotherapy-induced Nausea and Vomiting Drugs Products Offered
- 11.6.5 Novartis Recent Development
- 11.7 Heron Therapeutics
- 11.7.1 Heron Therapeutics Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Heron Therapeutics Chemotherapy-induced Nausea and Vomiting Drugs Products Offered
- 11.7.5 Heron Therapeutics Recent Development
- 11.8 Roche
- 11.8.1 Roche Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Roche Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Roche Chemotherapy-induced Nausea and Vomiting Drugs Products Offered
- 11.8.5 Roche Recent Development
- 11.9 Mylan
- 11.9.1 Mylan Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Mylan Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Mylan Chemotherapy-induced Nausea and Vomiting Drugs Products Offered
- 11.9.5 Mylan Recent Development
- 11.10 Tesaro
- 11.10.1 Tesaro Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Tesaro Chemotherapy-induced Nausea and Vomiting Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Tesaro Chemotherapy-induced Nausea and Vomiting Drugs Products Offered
- 11.10.5 Tesaro Recent Development
12 Future Forecast
- 12.1 Chemotherapy-induced Nausea and Vomiting Drugs Market Forecast by Regions
- 12.1.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Chemotherapy-induced Nausea and Vomiting Drugs Market Forecast by Product
- 12.2.1 Global Chemotherapy-induced Nausea and Vomiting Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Chemotherapy-induced Nausea and Vomiting Drugs Revenue Forecast by Product 2019-2025
- 12.3 Chemotherapy-induced Nausea and Vomiting Drugs Market Forecast by End User
- 12.4 North America Chemotherapy-induced Nausea and Vomiting Drugs Forecast
- 12.5 Europe Chemotherapy-induced Nausea and Vomiting Drugs Forecast
- 12.6 Asia Pacific Chemotherapy-induced Nausea and Vomiting Drugs Forecast
- 12.7 Central & South America Chemotherapy-induced Nausea and Vomiting Drugs Forecast
- 12.8 Middle East and Africa Chemotherapy-induced Nausea and Vomiting Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Chemotherapy-induced Nausea and Vomiting Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Chemotherapy-induced Nausea and Vomiting Drugs . Industry analysis & Market Report on Chemotherapy-induced Nausea and Vomiting Drugs is a syndicated market report, published as Global Chemotherapy-induced Nausea and Vomiting Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Chemotherapy-induced Nausea and Vomiting Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
